Zazo, Sandra; González-Alonso, Paula; Martín-Aparicio, Ester; Chamizo, Cristina; Cristóbal, Ion; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Eroles, Pilar; Lluch, Ana; Madoz-Gúrpide, Juan; Rojo, Federico
(e-Century Publishing, 2017)
Trastuzumab became the therapy of choice for patients with HER2-positive breast cancer in 1998, and it has provided clinical benefit ever since. However, a significant percentage of patients show primary resistance to ...